Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
Phase 4
- Conditions
- Essential Hypertension
- Registration Number
- NCT00366119
- Lead Sponsor
- Pacific Pharmaceuticals
- Brief Summary
The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
- mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg)
Exclusion Criteria
- 180mmHg≤SBP
- If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings
- If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings
- impaired hepatic function
- imapaired renal function
- angioedema
- aortic valvular stenosis or obstrcutive ejection disorder
- primary hyperaldosteronism
- renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis
- severe respiratory disease
- congestive heart failure( New York Association functional class Ⅲ or Ⅳ)
- malignant hypertension
- labile angina pectoris or myocardial infarction in the last 3 months before study entry
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Reduction of DBP(diastolic blood pressure)
- Secondary Outcome Measures
Name Time Method Reduction of SBP(systolic blood pressure) Percentage of patients with Dcrease of BP(blood pressure) Percentage of patients with a Normalization of BP(blood pressure) Artery stiffness(chang of pulse wave velocity) Left ventricular diastolic function Change of BNP Change of CRP
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, 28 Yeongeon-dong, Jongno-gu, Korea, Republic of